SCHEMBL6138568

SCHEMBL6138568

CCCCCCCCCCCCCCCCCOCCO

nearest known ligand 0.95

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.95
KMT2A Q03164 4/20 0.95
HTT P42858 2/20 0.95
THRB P10828 1/20 0.95
MAPT P10636 1/20 0.95
TSHR P16473 3/20 0.80
USP2 O75604 2/20 0.54
MAPK1 P28482 2/20 0.53
LMNA P02545 3/20 0.52
ALDH1A1 P00352 3/20 0.52
HSD17B10 Q99714 1/20 0.52
CES2 O00748 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.49
CYP3A4 P08684 1/20 0.49
CASP1 P29466 1/20 0.49
SLCO1B3 Q9NPD5 1/20 0.49
SLCO1B1 Q9Y6L6 1/20 0.49
CES1 P23141 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21828760 1.00 MEN1 (0.95) MEN1KMT2AHTTTHRBMAPT
SCHEMBL344085 1.00 MEN1 (0.95) MEN1KMT2AHTTTHRBMAPT
Di(Hydroxyethyl)Ether SCHEMBL2484145 1.00 MEN1 (0.95) MEN1KMT2AHTTTHRBMAPT
Di(Hydroxyethyl)Ether SCHEMBL23356733 1.00 MEN1 (0.95) MEN1KMT2AHTTTHRBMAPT
Di(Hydroxyethyl)Ether SCHEMBL23356816 1.00 MEN1 (0.95) MEN1KMT2AHTTTHRBMAPT
Di(Hydroxyethyl)Ether SCHEMBL23356871 1.00 MEN1 (0.95) MEN1KMT2AHTTTHRBMAPT
Di(Hydroxyethyl)Ether SCHEMBL23356793 1.00 MEN1 (0.95) MEN1KMT2AHTTTHRBMAPT
Di(Hydroxyethyl)Ether SCHEMBL23356787 1.00 MEN1 (0.95) MEN1KMT2AHTTTHRBMAPT
SCHEMBL185805 1.00 MEN1 (0.95) MEN1KMT2AHTTTHRBMAPT
Di(Hydroxyethyl)Ether SCHEMBL2124090 1.00 MEN1 (0.95) MEN1KMT2AHTTTHRBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260060240-A1 METHOD OF DEPRESSING VOLATILITY OF ORGANIC SOLUTES FROM THEIR AQUEOUS SOLUTIONS VIVE CROP PROT INC (CA) 2026-03-05 US claimed
US-20260060240-A1 METHOD OF DEPRESSING VOLATILITY OF ORGANIC SOLUTES FROM THEIR AQUEOUS SOLUTIONS VIVE CROP PROT INC (CA) 2026-03-05 US disclosed
CN-119367342-A CYP-eicosanoids analogs for treating or preventing diseases associated with neovascularization and/or inflammation 奥迈科斯治疗公司 2025-01-28 CN disclosed
CN-113717154-B Methods for treating huntington's disease PTC医疗公司 2024-11-15 CN disclosed
US-20240360163-A1 Nucleoside Prodrugs and Uses Related Thereto UNIV EMORY (US) 2024-10-31 US disclosed
CN-118613480-A Polycyclic IRAK and FLT3 inhibiting compounds and uses thereof 儿童医院医学中心 2024-09-06 CN disclosed
US-12049474-B2 Nucleoside prodrugs and uses related thereto EMORY UNIVERSITY (US) 2024-07-30 US disclosed
CN-117794939-A Antibiotic pyrazinothiazine derivatives and process for their preparation 巴格沃克斯研究印度私人有限公司 2024-03-29 CN disclosed
CN-110946865-B Methods for treating huntington's disease PTC医疗公司 2024-01-26 CN disclosed
CN-117015380-A Polycyclic IRAK and flt3 inhibiting compounds and uses thereof 儿童医院医学中心 2023-11-07 CN disclosed
CN-100371398-C Articles having a photochromic polymeric coating PPG IND OHIO INC (US) 2008-02-27 CN disclosed
CN-101056650-A Stable formulations of insulinotropic peptides NOVO NORDISK AS (DK) 2007-10-17 CN disclosed
CN-1281705-C Photochromic polymerizable compositions PPG IND OHIO INC (US) 2006-10-25 CN disclosed
EP-1058274-B1 Composition for film formation and material for insulating film formation JSR CORP (JP) 2005-07-27 EP disclosed
CN-1596291-A Photochromic polymerizable compositions PPG IND OHIO INC (US) 2005-03-16 CN disclosed
CN-1596289-A article having a photochromic polymeric coating PPG IND OHIO INC (US) 2005-03-16 CN disclosed
US-6376634-B1 ORGANOSILICON POLYMERS JSR CORPORATION (JP) 2002-04-23 US disclosed
EP-1058274-A1 Composition for film formation and material for insulating film formation JSR Corporation (JP) 2000-12-06 EP disclosed
EP-0025720-B1 PROCESS FOR THE MANUFACTURE OF MIXED PHOSPHORIC ACID ESTER COMPOSITIONS AND PLASTICISED POLYMERS CONTAINING THEM FMC Corporation (US) 1986-02-26 EP disclosed
EP-0025720-A1 Process for the manufacture of mixed phosphoric acid ester compositions and plasticised polymers containing them FMC Corporation (US) 1981-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260060240-A1 METHOD OF DEPRESSING VOLATILITY OF ORGANIC SOLUTES FROM THEIR AQUEOUS SOLUTIONS MYB, DRD1, SFN MEN1 4484/4885KMT2A 2694/4885HTT 2253/4885
US-20240360163-A1 Nucleoside Prodrugs and Uses Related Thereto PNPO, GSTO1, CYP2C18 MEN1 4325/4885KMT2A 3065/4885HTT 3975/4885
US-12049474-B2 Nucleoside prodrugs and uses related thereto PNPO, GSTO1, CYP2C18 MEN1 4325/4885KMT2A 3065/4885HTT 3975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.